Live Breaking News & Updates on Pulmonary Arterial

Stay updated with breaking news from Pulmonary arterial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

FDA Approves Sotatercept for Pulmonary Arterial Hypertension

Marius Hoeper, MD, offers expert perspectives on the recently FDA-approved sotatercept, focusing on its mechanism of action, potential cost implications, and potential advantages and disadvantages it could offer compared with existing foundational therapies. ....

Pulmonary Arterial ,

Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension

Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United States , Miltonh Werner , Milton Werner , Alex Lobo , Company Phase , Division Of Cardiology , Inhibikase Therapeutics Inc , Exchange Commission , Stern Investor Relations Inc , Company Contact , Inhibikase Or Company , Drug Administration , New Molecular Entity , Pulmonary Arterial Hypertension , Abelson Tyrosine Kinases , Investigational New Drug , Chief Executive Officer , Pulmonary Arterial , Arterial Hypertension , Abelson Tyrosine Kinase , Abelson Tyrosine , Multiple System Atrophy , Private Securities Litigation Reform Act , Investor Relations ,

New Drug Helps Patients With High Blood Pressure of the Lungs Breathe Easier

The FDA has approved sotatercept (Winrevair), a first-in-kind drug to improve exercise tolerance and functional class and slow the progression of pulmonary arterial hypertension. ....

United States , Heather Kauffman , Vallerie Mclaughlin , Nick Blackmer , Verywell Health , University Of Michigan Health , Drug Administration , Pulmonary Arterial , Michigan Health , New Type , Pulmonary Hypertension , Pulmonary Arterial Hypertension , Arterial Hypertension , Blood Pressure ,

Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension

Meeting to discuss potential of IkT-001Pro as a disease modifying treatment for Pulmonary Arterial HypertensionBOSTON and ATLANTA, April 03, 2024 Inhibikase Therapeutics, Inc. , a. ....

United States , Alex Lobo , Miltonh Werner , Milton Werner , Inhibikase Therapeutics Inc , Drug Administration , Stern Investor Relations Inc , Office Of Cardiology , Division Of Cardiology , Inhibikase Or Company , Exchange Commission , Company Contact , Pulmonary Arterial , Abelson Tyrosine Kinases , Pulmonary Arterial Hypertension , Chief Executive Officer , Arterial Hypertension , Abelson Tyrosine Kinase , Abelson Tyrosine , Multiple System Atrophy , Private Securities Litigation Reform Act , Investor Relations ,

Inhibikase Announces Pre-IND Meeting For IkT-001Pro

Inhibikase Therapeutics, Inc. (IKT) announced it will meet with the Office of Cardiology, Hematology, Endocrinology and Nephrology in the Division of Cardiology and Nephrology at the FDA for a Pre-IND meeting to discuss IkT-001Pro as a treatment for Pulmonary Arterial Hypertension. ....

Milton Werner , More Such Health News , Inhibikase Therapeutics Inc , Division Of Cardiology , Office Of Cardiology , Inhibikase Therapeutics , Pulmonary Arterial , Pulmonary Arterial Hypertension ,